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Abstract: Background. Damage to the myelin sheath (demyelination) is one of the main 
manifestations of multiple sclerosis (MS). Interestingly, both MS and vitamin B deficiency 
results in severe myelin degeneration that leads to loss in neuronal signal transmission. 
Objective. Deficiency in vitamin B complex vary, although common symptoms include  
fatigue, increased oxidative stress, inflammation and demyelination. In particular, vitamin 
B12 (cobalamin) has had increased attention for its role in the methylation process, 
involvement in myelination and re-myelination, and reversal of MS symptoms. Method. 
Here, we discuss the role of vitamin B complex (B1, B2, B3, B4, B5, B6, B7, B9, B12) in 
MS. Results. The anti-inflammatory and re-myelinating attributes of vitamin B complex 
members are promising, despite limited clinical studies. Conclusion. There is an urgent need 
for larger studies to determine the role of vitamin B supplementation alone, or in combination 
with other therapeutic agents, in prevention or reversal of MS, and aid in improved quality of 
life of MS patients.  
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1. INTRODUCTION   
Multiple sclerosis (MS) is an autoimmune neurodegenerative disorder associated with 
chronic inflammation of the central nervous systems (CNS) leading to axonal loss and 
demyelination [1]. Activated macrophages, autoreactive CD4 T cells, antibodies, Th1 
cytokines, T regulatory cells and Th17 cells against protein constituents of the myelin sheath 
(myelin basic protein, MBP; proteolipid protein, PLP; myelin oligodendrocyte protein, 
MOG) have been implicated in the pathogenesis of MS [2]. The onset of MS usually occurs 
in young individuals, aged 25-35 years and is more common (2:1) in females than males [2]. 
The disease manifests itself in a series of time-varying MS attacks where there are 
alterations/abnormalities in sensory, motor and/or cognitive function. Most symptoms are a 
result of axonal damage and neuronal loss as is seen in advanced and progressive stages of  
the disease, where myelin is destroyed in discrete areas of the brain or spinal cord (plaques of 
demyelination), resulting in impairment of axonal signalling and miscommunication [3]. 
MS is divided into four types, (i) relapsing-remitting (RR), (ii) primary-progressive 
(PP), (iii) secondary-progressive (SP), and (iv) progressive-relapsing (PR) [4]. RR is 
characterized by defined attacks of worsening neurologic function (relapses), followed by 
partial or complete recovery periods (remission). Almost 85% of individuals diagnosed with 
MS are RR onset type and 10% of progressive onset type. PP is characterized by steady 
worsening of neurologic function from the initial diagnosis with no distinct relapses and 
remissions. Approximately 2/3 of patients with RR MS will eventually develop SP MS, 
which progresses more steadily with or without ongoing relapses. The least common type of 
MS is PR, and is characterized by the steady progression of the disease from the beginning 
with occasional violent exacerbations [4].  
In MS, damage to the myelin fibre (demyelination) is the most common outcome, 
where severe degeneration could lead to a block in neuronal communication and loss of 
conductance. The symptoms are variable between patients and are largely dependent on the 
location and the severity of the affected area [1]. The most common sites of demyelination 
are within the optic chiasm and nerves, the brainstem, cerebellum, upper spinal cord and 
cerebrum; periventricular, pericallosal and subcortical are common lesion locations. As a 
result, immobility, spasticity and motor-sensory problems become an issue. Complete axonal 
degeneration occurs in the later chronic progressive stage (PR) of the disease resulting in 
permanent disability [5].  
Interestingly, vitamin B is a broadly available potent modulator of the re-myelination 
process and its deficiency could possibly have detrimental effects in MS progression. There is 
increasing interest towards the link between vitamin B deficiency and its involvement in MS 
development and progression. Herein, we review the putative role of vitamin B group in the 
prevention of MS development and progression. 
 
2. VITAMIN B AND HEALTH 
 Vitamin B constitutes a collection of water-soluble vitamins, including B1 (thiamine), 
B2 (riboflavin), B3 (nicotinamide), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 
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(folic acid), and B12 (cyanocobalamine), each with distinct functions. As a complex, B 
vitamins are required for proper functioning of the methionine and folate cycles, methylation 
cycle, monoamine oxidase production, DNA synthesis, repair and maintenance of lipids, 
including myelin [6-9]. The methylation cycle is responsible for detoxification, immune 
function, mood, and controlling inflammation. A defect in methylation function contributes to 
numerous chronic conditions, including some neurological conditions [7-9]. Monoamine 
oxidase plays a vital role in the inactivation of neurotransmitters and a dysfunction in 
monoamine oxidase is thought to be responsible for a number of psychiatric and neurological 
disorders, including schizophrenia, depression and MS [7, 10-12]. It is apparent that vitamin 
B plays a role in the maintenance of human neurophysiology and may thus have an important 
regulatory role in MS.  
 
3. WHAT ROLE DOES VITAMIN B PLAY IN MS? 
Despite current advances in MS research, the disease aetiology remains unknown, 
although genetic susceptibility to disease, mimicry between viruses and proteins within the 
myelin sheath, immune cells (i.e. Th1, Th17 antibodies), vitamin D deficiency, insufficient 
nutrition, stress and demographics have been suggested, Fig. (1) [13-18]. Prevention of acute 
inflammatory myelin damage at early, as well as at the late stage, and promotion of neuro-
regeneration can provide better quality of life to MS patients regardless of the type and stage 
of disease [19].  
Whilst each vitamin B has a role in human health, the general association of vitamin 
B deficiency in MS patients is often linked with chronic fatigue, inflammatory diseases and 
neuronal demyelination. Vitamin B complex has been implicated to have a modulatory role in 
the pathophysiological process of MS, Fig. (1) (see below sections 3.1-3.8). 
 
 4 
 
Fig. (1). Vitamin B complex modulation of MS: Vitamin B complex are all involved directly or indirectly 
in neurodegenerative disease prevention.  
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3.1. The role of vitamin B1 (thiamine) in MS 
Vitamin B1 (thiamine) is present in most foods, such as brewer’s yeast, meat, tuna, 
cereals, breads, legumes, and nuts. Thiamine is required to process carbohydrates into energy, 
as well as RNA and DNA production, and psychological and nerve function [20]. Patients 
with MS experience fatigue which has been linked to intracellular thiamine deficiency. 
Indeed, in a pilot study of 15 patients with RRMS in remission with symptoms of fatigue, 
administration of high dose of thiamine (600 – 1,500 mg/day; 1.2 mg is the recommended 
daily intake) resulted in fatigue regression as evaluated by the fatigue severity scale [21]. 
Importantly, despite the high dose of thiamine used, no side effects were reported. Thiamine 
deficiency causes impaired oxidative metabolism due to poor enzymatic activity of thiamine-
dependent proteins causing a series of symptoms, such as, decreased energy, increase in 
oxidative stress, lactic acidosis, astrocyte dysfunction, disruption of the blood-brain barrier, 
decreased cellular glucose uptake and chronic inflammation [22]; interestingly, these are also 
symptoms of MS. In a mouse model of MS, experimental autoimmune encephalomyelitis 
(EAE) induced by myelin oligodendrocyte glycoprotein encephalitogenic peptide, MOG35-55, 
the disease severity is exacerbated in thiamine-deficient mice compared to non-thiamine 
deficient mice. The deficient mice showed pathologic alterations in the spinal cord, 
microglial activation and increased Th1 and Th17 cell infiltration and increased expression of 
chemokine, CCL2, in the spinal cord [23], compared to non-deficient mice. CCL2 is involved 
in recruiting monocytes, dendritic cells and memory T cells at sites of inflammation. Thus, 
there is preliminary evidence that suggests some potential role of thiamine in MS, however 
these need to be substantiated in larger studies. 
 
3.2. The role of vitamin B2 (riboflavin) in MS 
Vitamin B2 is present in yeast, liver, milk, meat, eggs, green vegetables and fortified 
cereals. Its main function is to convert carbohydrates into glucose, neutralize free radicals, 
such as reactive oxygen species (ROS) and maintain normal vision, normal red blood cells, 
normal function of the nervous system and myelin formation in nerve cells. In addition, 
riboflavin interacts with vitamin B6 and B9, converting them into their active forms. 
Riboflavin deficiency is usually associated with fatigue, eye irritation and sore throat [20]. 
ROS are chemically reactive molecules containing oxygen ions and peroxides and are 
involved in normal homeostasis. However, during stress the levels of ROS increase 
dramatically leading to oxidative damage to neuronal membrane lipids, proteins, RNA and 
DNA [24]. In MS, this contributes to initiation and persistence of lesions, by disrupting the 
blood–brain barrier, increasing inflammation and demyelination. Indeed, in active 
demyelinating lesions, there is extensive oxidative damage primarily to astrocytes and 
myelin-laden macrophages which can be reversed by endogenous antioxidant enzymes [24]. 
Riboflavin exhibits anti-inflammatory and antioxidant properties and its protective effect 
against MS was noted in a study of 197 MS patients [25]. In this case-control study, 197 
patients with MS and 202 age and sex matched control subjects completed a 164-item food 
frequency questionnaire. An inverse association was noted between protective effects with 
intake of vegetable protein, thiamine, riboflavin, calcium and potassium. Hence, nutritional 
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factors in this cohort appear to be associated with risk/aetiology of MS. However, in a 
randomized double blind trial where 29 patients with MS received riboflavin (10 mg) for six 
months compared to a placebo group there were no improvements noted to MS symptoms 
[26]. It is difficult to compare these two studies, as the samples and study designs were 
different, different end points, as one assessed food intake whereas the other determined the 
effects of riboflavin supplementation over six months. Of relevance, in EAE, an animal 
model of MS, brain-derived neurotrophic factor (member of the neurotrophin family of 
growth factors) was increased in the brain and spinal cord of mice treated with riboflavin for 
two weeks, and EAE symptoms were significantly reduced, compared to sham or interferon 
beta-1a treated mice [27]. Hence, riboflavin appears to have immunomodulatory effects, 
exerts protective effects against oxidative damage and demyelination; however, further 
research is required to ascertain its role in MS.  
 
3.3. The role of vitamin B3 (niacin) in MS 
Vitamin B3, or niacin, is found in two forms, nicotinamide and nicotinic acid. The 
synthesis of niacin requires tryptophan, which is obtained from foods, mostly seafood, or by 
dietary supplements [28]. Niacin is also found in yeast, liver, chicken, red meat, legumes and 
nuts [20]. Interestingly, coffee also provides significant amounts of nicotinic acid, and one 
cup of coffee provides the daily allowance of vitamin B3. Niacin acts as a co-factor for the 
conversion of carbohydrates into glucose, aids in the production of fatty acids and 
cholesterol, and influences cellular processes that repair DNA damage and normal 
psychological and biochemical functions of the nervous system. Its deficiency is associated 
with fatigue, dementia and depression [20]. 
Interestingly, over 40 years ago, observational studies by a physician where he 
administered large doses of nicotinamide (100 mg, 30 minutes before meals and bed) and 
thiamine (300 - 500 mg, 30 minutes before meals and bed) to patients with MS was able to 
arrest and reverse MS symptoms and repair damaged nerve cells [29]. Recently, the interest 
in using vitamins to treat MS has resurfaced. Of anecdotal interest, a Mongolian patient with 
MS had severe deficiency of micronutrients, including niacin, which may have played some 
role in his MS diagnosis [30]; albeit weak evidence with only one patient. In animal models 
of MOG-induced and PLP-induced EAE, daily injections of 500 mg/kg of nicotinamide 
significantly improved behavioral scores and EAE symptoms. Histologically, mice injected 
with nicotinamide showed significantly reduced areas of immune cell infiltration and 
demyelination. Furthermore, nicotinamide protected against axonal damage in an in vitro 
model for microglia-mediated neurotoxicity (lipopolysaccharide-activated microglia). Hence, 
together the in vivo and in vitro data suggests that nicotinamide has a direct neuroprotective 
role. Moreover, in a therapeutic setting of EAE, where nicotinamide (500 mg/kg) was 
administered into mice which had already developed EAE, areas of inflammation and 
demyelination were reduced, axonal loss was significantly prevented and the behavioral score 
was significantly reduced compared to control mice [31]. Further research is required to 
underpin the role of niacin in MS; however, nutritional treatment studies using niacin may be 
an effective approach to alleviating disease outcomes or protecting against MS. 
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3.4. The role of vitamin B4 (choline) in MS 
 Vitamin B4 (also referred to as, choline, adenine, carnitine) is classed with B vitamins 
based on its chemical structure, is a crucial component of myelin, but its main action is as a 
cholinergic substance and the primary constituent of the neurotransmitter acetylcholine. 
Acetylcholine is predominantly involved in parasympathetic nervous system function and is 
found at preganglionic neurons and neuromuscular junctions. Interestingly, acetylcholine 
supplementation alleviates injury and alters spinal cord lipid content in MOG-induced EAE 
mice [32]. Furthermore, choline plays an important role in cell signalling and function, and is 
important in cell membrane structure and plasma lipoproteins. Choline is significantly 
elevated in patients with RRMS [33], as well as being increased in pre-lesional normal-
appearing white matter in MS [34]. A mechanism to enhance myelin repair via the choline 
pathway was identified [35], where choline exerted neuroprotective and regenerative 
properties in two EAE animal models. It was noted that clinical symptoms in a MOG-induced 
EAE model were reduced when injected prior to EAE induction but not once EAE was 
induced, suggesting a role of choline in protecting against disease initiation. However, in the 
cuprizone EAE model where immune cells are not the primary effectors in EAE but rather 
oligodendrocyte death due to the toxic effects of cuprizone, choline enhanced myelin repair 
and reversed motor coordination deficits. In addition, choline was shown to increase the 
proliferation of oligodendrocyte precursor cells (OPC) in vitro [35, 36]. In fact, for re-
myelination to occur effectively, recruitment of oligodendrocyte progenitor cells (OPC) 
needs to occur at lesion sites; they must differentiate into mature cells capable of initiating 
myelination and repair of the demyelinated axon [37]. In the quest to enhance myelination 
therapeutically for patients with MS, much attention has concentrated on promoting 
endogenous repair mechanism either via control of OPC proliferation, maturation and 
differentiation, or by transplanting myelinating cells directly into lesions, although the later 
poses some ethical concern as the process uses stem cells therapy [38]. It is apparent that 
choline has therapeutic potential against MS; however, further research is required to 
ascertain the role of choline in MS. 
 
3.5. The role of vitamin B5 (pantothenic acid) in MS 
 Pantothenic acid (or pantothenate, vitamin B5) is found in all foods (small quantities); 
however high quantities are primarily in yeast and organ meats (i.e. liver, brain, kidneys, 
heart), and to a certain extent in avocado, eggs, milk, legumes and fortified cereals [20]. 
Pantothenic acid is the immediate precursor to co-enzyme A and is involved in metabolism of 
fats, carbohydrates and protein for energy generation [39]. It is involved in the formation of 
red blood cells, amino acids, fatty acids, cholesterol, phospholipids, vitamin D, sex hormones 
and aids in healthy mental performance. Pantothenic acid deficiency is rare and has not been 
thoroughly studied; however, in the few cases studied (i.e. extreme starvation or malnutrition) 
symptoms include fatigue, insomnia, depression and increased susceptibility to respiratory 
infections [20]. 
 Pantothenic acid regulates, iron, oxygen transport in the brain, electron transfer, 
neurotransmitter synthesis, myelin production and facilitates myelin regeneration. However, 
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high levels of iron can be detrimental, leading to free radical production and neurotoxicity. 
High iron levels in the brain have been noted in a number of neurological disorders, 
including, Parkinson’s disease, Alzheimer’s disease, and MS, even though the underlying 
pathological processes in the brain are not well-understood [40]. In light of the beneficial and 
detrimental properties of iron in MS, and pantothenic acid’s role in the  regulation of iron, 
sufficient iron levels are required for re-myelination and repair whilst avoiding excess that 
might contribute to damage [41]. Further research is required to determine the role of 
pantothenic acid in relieving MS symptoms and whether pantothenic acid has a direct or 
indirect effect. 
 
3.6. The role of vitamin B6 (pyridoxine) in MS 
Vitamin B6 is comprised of three interrelated isoforms, pyridoxine, pyridoxal, and 
pyridoxamine. All three pyrimidine derivatives occur naturally and are endogenously 
converted to pyridoxal 5’-phosphate [42]. Pyridoxine is found in chicken, liver, pork, fish, 
nuts, bread, cereals [20, 43]. Pyridoxine assists in the synthesis of haemoglobin which is 
important for red blood cells, aids in the production of hormones (serotonin, melatonin and 
dopamine) which influence mood, and melatonin which helps regulate the circadian rhythm. 
It is known for its involvement in neurotransmitter formation and is an essential nutrient in 
regulation of neuronal activities and integrity [44]. However, high supplementation levels 
may cause sensory nerve damage. Pyridoxine deficiency is uncommon; however, people with 
such deficiency present with nervous system disorders (depression, confusion, irritability), 
impaired immune system and inflammation [20]. In infants fed with autoclaved formula, 
where pyridoxine is destroyed, hyper-irritability and epileptic-type seizures were reported; 
administration of the vitamin reversed symptoms [45]. In addition, clinically low pyridoxine 
levels (< 20 nmol/L) are not uncommon in autoimmune disorders, as noted in rheumatoid 
arthritis [46] and type I diabetes [47]. In fact, in an observational cross-sectional study of 43 
patients with rheumatoid arthritis, patients were put into two groups, (i) <20 nmol/L (n=30, 
deficient pyridoxine levels) or (ii) >20 nmol/L (n=13, adequate pyridoxine levels). Those in 
the deficient pyridoxine group were found to have high inflammation as measured by C-
reactive protein and higher T cell numbers [46]. In addition, in 32 type 1 diabetic patients and 
27 matched healthy controls it was noted that type 1 diabetes altered the metabolism of 
pyridoxine leading to increased risk of pyridoxine deficiency and diabetic complications [48]. 
Furthermore, studies conducted over 40 years ago demonstrated that pyridoxine deficiency 
directly lead to demyelination in animals models of mice and rats. In addition, impaired 
immune responses of MS patients and pyridoxine deficiency were inter-correlated in regards 
to impaired antibody and delayed hypersensitivity reactions [49]. Follow-up studies are 
considerably overdue, further work is required to determine the role of pyridoxine in MS. 
 
3.7. The role of vitamin B7 (biotin) in MS 
Vitamin B7 (biotin, coenzyme R, vitamin H) is found in yeast, peanuts, soybeans, 
almonds, walnuts, milk, raw egg yolk, liver, kidney and green leafy vegetables. Biotin is 
required for cell growth, maintenance of blood sugar levels, strengthening hair and nails, and 
it is a coenzyme for carboxylase enzymes involved in the synthesis of fatty acids and amino 
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acids. Biotin deficiency is extremely rare as biotin is synthesized by gut flora. However, 
when deficiency is present, symptoms include hair loss, dry skin, conjunctivitis, dry eyes, 
dermatitis, insomnia and neurological symptoms, i.e. depression, hallucinations, muscle pain 
and numbness and tingling of fingers and toes [20]. 
There is limited research in the MS field related to the role of biotin in MS. However, 
in serum and cerebrospinal fluid of 170 patients with various neurological disorders (33 MS, 
13 motor neuron disease, 13 with dementia, 17 with epilepsy, 18 with polyneuropathy and the 
remainder were grouped as various neurological disorders group) and 68 age and sex 
matched controls significant differences were noted in biotin levels. Only patients with MS 
(79+28 mg/L) or epileptics (82+21 mg/L) showed significant reduced levels of biotin in 
cerebrospinal fluid compared to controls (136+75 mg/L; p=0.001) [50]. In addition, 
supplementation with high doses of biotin (MD1003; 100-300 mg) in an open-label pilot 
study in 23 patients with primary and secondary progressive MS, showed positive effects 
with a treatment period of 3-12 months. Effects included improvement of neurological 
disability, even after a long period of motor deficit, significant improvement in visual acuity, 
and, improvement in the homonymous lateral hemianopia [51]. Furthermore, in a randomized 
double-blind placebo controlled clinical study in 154 patients with RRMS, high dose of 
MD1003 (100 mg) resulted in reduced Expanded Disability Status Scale (EDSS) progression 
and improved clinical impression of change compared to placebo group. MD1003 was shown 
to be safe and achieved sustained reversal of MS related disability in 13 patients with 
progressive MS [52]. These studies suggest that biotin plays a role in MS; however, further 
research is required to determine the role of biotin deficiency in MS and the mechanism of 
action of high dose biotin supplementation in MS patients. 
 
3.8. The role of vitamin B9 (folate) in MS 
Vitamin B9 (folate, folic acid, vitamin M, vitamin BC) from the Latin word ‘folium’ 
meaning ‘leaf’ is found in dark green leafy vegetables, as well as, in beans, wheat, yeast, 
eggs, milk and orange juice [20]. Folate, or folic acid, is required in the methylation of 
homocysteine to methionine and in the synthesis of S-adenosyl-methionine. S-adenosyl-
methionine is involved in the methylation reactions of proteins, DNA, lipids and 
neurotransmitter metabolism. Insufficient folate levels is best known to cause deformation of 
the newborn although, other symptoms include fatigue, megaloblastic anemia and aggravates 
depressive disorders. 
Serum and cerebrospinal fluid folate levels in 293 patients (with MS, Alzheimer’s 
type dementia, non-Alzheimer’s type dementia or myelopathy) and 157 control subjects did 
not show significant differences between the various groups [53, 54]. However, it has been 
suggested that low or reduced levels of folate found in MS patients may be related to 
previous corticosteroid treatments [55]. In a cross-sectional study in 101 RR MS patients, 
nutritional status and its relationship with fatigue in MS was determined. Fatigue was 
measured using the Modified Fatigue Impact Scale (MFIS), dietary intake was measured via 
a 3-day food record questionnaire and compared to dietary reference intake (DRI) values. The 
data suggests that daily intake of folate as well as vitamin D, calcium and magnesium were 
significantly lower than the DRI in all patients and MFIS correlated with folate intake; 
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suggesting that low folate diets correlate with high fatigue in patients with MS [56]. 
Interestingly, folic acid supplementation (200-300 µg/day) to patients with MS improved the 
neurological status of patients, promoted myelin regeneration and the overall general 
condition and symptoms [57, 58]. Conversely, in the Kaiser Permanente study, 22 patients 
with MS received a short course of immunosuppression (cyclophosphamide 400-500 mg) and 
was compared to 20 patients with MS who were supplemented with folic acid (1 mg, 5 
times/week for 2 weeks), showed similar disease progression in both groups [59]. 
Undoubtedly, folate is an important regulatory molecule that could prevent 
methylation related alterations that contribute to demyelination. Insufficient research linking 
the association between folate and MS begs for more clinical investigations and opens a new 
outlook on folate / folic acid metabolism and its importance in neurodegenerative diseases, 
such as MS.  
 
3.9. The role of vitamin B12 (cobalamin) in MS 
Vitamin B12 comprises the only cobalt-containing molecules (cobalamin) that is 
associated with many biological functions. Cobalt gives vitamin B12 its red colour [20]. It is 
produced by microbial synthesis in the gut and the primary source of B12 is in organ meats 
(liver, kidney, heart); other sources include fish, eggs and milk. Even though B12 is 
synthesized in the gut, B12 intake from the diet is required. B12 is involved in cellular 
metabolism of carbohydrates, proteins and lipids, and acts as a co-factor in myelin formation 
and physiology of the nervous system and for immune mechanisms. Vitamin B12 also acts as 
co-enzyme for methionine synthase reaction with methylcobalamin and the methylmalonyl 
CoA mutase reaction with adenosylcobalamin. Low levels of B12 symptoms include, fatigue, 
nervousness, numbness or tingling of fingers and toes and in severe deficiency, neurological 
damage [20]. As B12 is not found in plant products or wheat, it makes B12 deficiency a 
concern in vegans. 
 
3.9.1 Vitamin B12 deficiency   
 Between the 1950s - 1960s there was a vast interest in vitamin B12 levels and MS 
with > 15 papers published (PubMed search term vitamin B12 and multiple sclerosis). The 
data was inconsistent, with studies showing lower B12 concentrations and others showing no 
difference in MS patients compared to controls. In the last decade, this interest has 
resurfaced.  
 In 35 MS patients during relapse, lower levels of serum vitamin B12 were noted 
compared to 30 healthy controls  [60]. Likewise, in 75 patients with RRMS, serum B12 levels 
were significantly lower compared to 75 healthy controls [61]. In addition in another study, 
10 MS patients were evaluated for B12 deficiency and there was a clear correlation between 
low vitamin B12 levels and MS [62]. However, in a Japanese cohort of 24 patients with MS 
and 73 patients with other neurological disorders there were no difference in B12 serum 
levels compared to 21 healthy controls [63]. Moreover, in 60 MS patients in remission there 
was no association between B12 deficiency and MS [64]. Cerebrospinal fluid levels of B12 in 
293 neurological patients was correlated with low B12 concentrations in patients with 
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Alzheimer’s type dementia and MS [53]. Similarly, in a meta-analysis study in MS patients, 
raised homocysteine levels and low B12 levels were associated with the pathogenesis of MS 
(extracted from 8 reports on the role of homocysteine levels in MS and from 8 reports on the 
role of B12 levels in MS) [65]. There appears to be an association between the age of onset of 
MS and B12 deficiency; B12 deficiency was strongly correlated in MS patients where the 
onset of first neurological symptoms was before 18 years, as compared to patients whose 
disease first manifested after the age of 18 [66]. 
 
3.9.2 Vitamin B12 supplementation  
Methylcobalamin therapy may provide the basis for improved treatments for MS. In 
fact, using neurite outgrowth assays of neurons isolated from rats, culturing with high doses 
of methylcobalamin (100 nM) improves neurite outgrowth and neuronal survival in vitro, as 
well as improving nerve regeneration and functional recovery in regards to neuronal axonal 
length and thickness of re-myelination in vivo following high dose administration of 
methycobalamin (1 mg/kg/day) without causing any side effects [67]. Vitamin B12 is 
required for the formation of methionine from homocysteine in the methylation cycle that 
involves methylation of DNA. Vitamin B12 enzyme, methionine synthase, is involved in 
catalyses of methyl group transfers from N5-methyltetrahydrofolate, resulting in synthesis of 
tetrahydrofolate and methionine. In addition, in mouse neuroblast cells, the addition of 
vitamin B12 into the media produced protective effects in cells subjected to stress stimulation 
[68]. Hence, B12 deficiency or lack of methionine synthase enzymatic activity can result in 
severe neurodegeneration and stress [69]. The proposed regenerative mechanism of vitamin 
B12 actions on the nervous system is shown in Fig. (2).  
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Fig. (2). Vitamin B 12 regulation of DNA methylation acetylation and re-myelination. Vitamin B12 
activates methionine synthase, which catalyses the synthesis of methionine. Methionine is the precursor of S-
adenosyl-methionine. S-adenosyl-methionine is the primary methyl donor in vitamin B12 metabolism, which 
acts as methyl group donor for methylation of various molecules such as DNA, RNA, proteins, phospholipids 
(including myelin). S-adenosyl-methionine converts to S-adenyl-homocysteine and after hydrolysis, results in 
homocysteine. Homocysteine is usually at elevated levels and vitamin B12 at low levels in MS patients. DNA 
and various histone chemical modifications determine gene expression and disease progression. DNA present 
around histones determines gene expression that influences the re-myelination process. Gene expression 
modulation of re-myelination process can be activated or repressed by availability of the accessible DNA that 
involves the methylation process and availability of B12. Co+ = Cobalt; R = 5’-deoxyadenosyl,Me,OH,CN; 
Vitamin B12 (cobalamin) structure consists of Dimethylbenzimidazole and a Corrin ring with Cobalt ion.  
 
 The effects of high methylcobalamin (B12) supplementation (60 mg/day for 6 
months) in 6 patients with chronic progressive MS, resulted in improved visual and brainstem 
auditory evoked potentials [63]. In a randomized placebo controlled, double blind study in 
138 patients with MS, B12 (1 mg) given intramuscularly for 24 weeks, improved by 2 Guy’s 
neurological disability scale (GNDS) points which according to the scale this is a significant 
improvement [70]. The limited number of human studies using vitamin B12 supplementation 
in MS patients, places a question mark on what would happen if B12 would be routinely used 
for MS treatment and prevention. Likewise, in animal models of EAE, B12 supplementation 
with interferon-beta improves demyelination and reduces astrocytosis and results in near 
normal motor function [71]. Furthermore, B12 supplementation together with paclitaxel 
significantly reduced clinical signs of EAE in mice, astrocytosis reversed back to normal, 
interferon-gamma was reduced and T cell expansion was suppressed [72].  
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 The continuous administration of high dose B12 should be further evaluated, as it aids 
in myelin recovery and other symptom improvement and may be beneficial to MS patients 
and may aid in the delay of relapses and disease progression associated with MS.  
 
3.9.3 Vitamin B12 deficiency and MS symptoms: similarities and differences 
Vitamin B12 deficiency is involved in a number of disorders, such as, peripheral 
neuropathy, autonomic nervous system dysfunction, optic nerve degeneration, depression, 
memory impairment, cognitive decline and mood and behavioral changes [73]. Patients with 
B12 deficiency also present with clinical and paraclinical characteristics that are similar to 
those seen in MS patients (Table 1). Vitamin B12 deficiency and MS are different clinical 
and pathological conditions, however, share similarity in loss of neuronal myelination and a 
range of other symptoms (Table 1). For example, B12 deficiency results in visual 
disturbances and brainstem auditory and somatosensory evoked responses which correlate 
with neurological dysfunction, similarly to the symptoms of MS patients [74]. Given the 
similarities in the clinical presentation and MRI findings, the differential diagnosis between 
B12 deficiency and MS may be difficult.  
It is difficult to distinguish between the neurological dysfunction caused by MS or 
B12, and whether MS could be due to vitamin B12 deficiency. Perhaps, chronic vitamin B12 
deficiency is a direct predisposition for MS development? Although other factors need to be 
considered, such as omega 3 and vitamin D deficiency (refer to paper by Simpson et al in this 
issue), environmental and genetic factors [75-78]. Nevertheless, further research is required 
to determine if there is a link between vitamin B12 and MS. 
 
Table 1. Vitamin B12 deficiency versus MS symptoms: The symptoms of vitamin B12 deficiency 
and MS are almost identical in description. It is not clear if these 2 conditions are interrelated or 
B12 deficiency has a role MS development and progression 
 
Vitamin B12 deficiency  
 
 
Reference 
 
MS Symptoms 
 
Reference 
Sensory and motor function 
malfunction 
[79-82] Sensory and motor function 
malfunction 
[83-85] 
Vestibulocochlear damage, 
changes in auditory signal 
reception, balance problem, 
dizziness, nausea, vomiting  
[86] Vestibulocochlear damage, 
changes in auditory signal 
reception, balance problem, 
dizziness, nausea, vomiting  
[83, 87, 88] 
Visual impairment that causing 
double vision, inability to focus 
on the object, optical motor 
function dysregulation 
[89] Visual impairment that causing 
double vision, inability to focus on 
the object, optical motor function 
dysregulation 
[90-92] 
Cranial nerve damage, including 
thermoregulation, sensory, audio-
optical-gustatory impairments, 
dysarthria 
[89] Cranial nerve damage, including 
thermoregulation, sensory, audio-
optical-gustatory impairments, 
dysarthria 
[93-96] 
Tingling sensations, tremor, 
numbness of the limbs, 
involuntary movements  
[97] Tingling sensations, tremor, 
numbness of the limbs 
[98-101] 
Muscular pain and spasm [97, 102] Muscular pain and spasm [3, 84] 
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Smooth muscles malfunction, 
including swallowing difficulty   
[103] Smooth muscles malfunction, 
including swallowing difficulty   
[104, 105] 
Fatigue, lack of energy and 
weakness  
[106] Fatigue, lack of energy and general 
weakness  
[107-111] 
Bladder and sexual incontinence  [112, 113] Bladder and sexual dysfunctions [114-117] 
Cognitive deterioration, memory 
loss, dementia, language 
problems, emotional instability, 
irritability, depression. 
[82, 118-
126] 
Cognitive impairments, such as 
memory problems, shortened 
attention span, language problems, 
emotional instability, irritability, 
depression 
[127-130] 
Macrocytic anemia, high 
homocysteine levels, memory 
loss, cognitive decline, paralysis 
[131] Macrocytic anemia, high 
homocysteine levels, memory loss, 
cognitive decline, paralysis 
[60, 61] 
 
 
4. CONCLUSION 
A considerable amount of work is still required to completely understand the 
neurological degradation of MS and all ameliorating processes associated with it. Despite 
studies in the last century, there is no therapy for MS patients, despite the number of new and 
improved treatment options available to them [132]. It is necessary to identify the potent 
supplement that exerts neuronal recovery and accelerated re-myelination process. So far, 
individual vitamin B compounds appear to have properties that promote re-myelination and 
inhibit inflammation to constituents of the myelin sheath. However, the lack of prospective 
clinical studies, places a large demand on research to determine the role of vitamin B 
compounds in MS, and its supplementation as a therapeutic against MS. In as such, vitamin B 
compounds hold promise for further research in defining it role in prevenation and/or 
treatment of MS 
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